SCHEMBL2193102

SCHEMBL2193102

Cn1nc(-c2ccccc2)[nH]c1=[Pt].Fc1ccc(CN(I)I)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 3/20 0.40
CYP19A1 P11511 1/20 0.37
NPC1 O15118 1/20 0.36
LMNA P02545 3/20 0.34
MAPT P10636 3/20 0.34
MAPK13 O15264 3/20 0.33
MAPK12 P53778 3/20 0.33
MAPK11 Q15759 3/20 0.33
MAPK14 Q16539 3/20 0.33
GCGR P47871 2/20 0.33
CSF1R P07333 2/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
ALDH1A1 P00352 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
PKM P14618 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197165 0.91 CSF1R (0.38) ALOX5LMNAMAPTCSF1RALDH1A1
SCHEMBL2193790 0.89 CYP19A1 (0.38) CYP19A1NPC1LMNAMAPTCSF1R
SCHEMBL2193608 0.88 MAPK13 (0.36) MAPTMAPK13MAPK12MAPK11MAPK14
SCHEMBL2194610 0.88 CYP19A1 (0.37) CYP19A1LMNAMAPTMAPK13MAPK12
SCHEMBL2195584 0.87 CXCR2 (0.38) CYP19A1MAPK13MAPK12MAPK11MAPK14
SCHEMBL2192771 0.84 LMNA (0.33) LMNACSF1RKDM4EMEN1KMT2A
SCHEMBL2196864 0.82 CACNA1G (0.36) ALOX5LMNAMAPK13MAPK12MAPK11
SCHEMBL2198377 0.75 CYP19A1 (0.39) CYP19A1NPC1LMNAMAPTMAPK13
SCHEMBL2193784 0.74 MAPK14 (0.36) LMNAMAPK13MAPK12MAPK11MAPK14
SCHEMBL2195930 0.74 GAA (0.34) MAPTALDH1A1SMN1; SMN2KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 ALOX5 986/4885CYP19A1 787/4885NPC1 3384/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 ALOX5 986/4885CYP19A1 787/4885NPC1 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.